We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03204890
Previous Study | Return to List | Next Study

TPTNS for Treating Patients With Premature Ejaculation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03204890
Recruitment Status : Completed
First Posted : July 2, 2017
Last Update Posted : February 4, 2019
Information provided by (Responsible Party):
Boston Medical Group

Brief Summary:

Background: Transcutaneous posterior tibial nerve stimulation is an effective therapy for controlling urinary incontinence. Premature ejaculation (PE) and urinary incontinence are anatomically and physio-pathologically similar. Based on this, the use of this therapy is considered to be viable for the control of PE.

Objective: To evaluate the efficacy of transcutaneous posterior tibial nerve electrostimulation for the ejaculatory reflex.

Patients and Methods: Phase II clinical trial. Patients with a diagnosis of premature ejaculation who are treated at the Colombia Boston Medical Group clinic will be included. The participants will receive 3 transcutaneous posterior tibial nerve stimulation therapies per week for 12 weeks. The IELT and the PEDT scale will be evaluated on week 6, at the end of treatment and three months after completing the protocol.

Condition or disease Intervention/treatment Phase
Premature Ejaculation Other: Transcutaneous Posterior Tibial Nerve Stimulation Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) for Treating Patients With Premature Ejaculation. Phase II Clinical Trial
Actual Study Start Date : June 14, 2017
Actual Primary Completion Date : January 15, 2018
Actual Study Completion Date : October 30, 2018

Arm Intervention/treatment
Experimental: TPTNS
Transcutaneous Posterior Tibial Nerve Stimulation
Other: Transcutaneous Posterior Tibial Nerve Stimulation
Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.

Primary Outcome Measures :
  1. Clinical improvement [ Time Frame: Three months after completion. ]
    Proportion of patients with clinical improvement of premature ejaculation, defined as a tripling of the baseline time (without treatment), as measured by the IELT (intravaginal ejaculation latency time)

Secondary Outcome Measures :
  1. Change in the basal PDET score [ Time Frame: Three months after completion. ]
  2. Magnitude of the change in the PEDT score [ Time Frame: Three months after completion. ]
  3. Frequency and severity of adverse events [ Time Frame: During the therapy ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Over 18 years of age and less than 50 years of age with no cardiovascular risk factor other than age.
  • Having been diagnosed with primary premature ejaculation according to the American Psychiatric Society's DSM 5 Diagnostic and Statistical Manual.
  • Agreeing to participate and providing signed informed consent.
  • Stable relationship for over 6 months, with frequent intercourse at least once per week.

Exclusion Criteria:

  • Diagnosis of erectile dysfunction according to the IIFE 5 (score under 21).
  • A PEDT score under 8.
  • Use of treatment for premature ejaculation during the study or over the 6 months prior to beginning the study.
  • Use of pacemaker or heart defibrillator.
  • Epilepsy or convulsions
  • Venous insufficiency (varices) or cutaneous wounds or injuries on the lower extremities.
  • Congenital or acquired anatomical abnormalities of the penis.
  • Taking medications that affect ejaculation control, including psychiatric medications, opioid analgesics and medications for pathologies of the prostate such as alpha blockers.
  • Psychological or psychiatric disorders that prevent the patient from undergoing the treatment or recording the measurements as established.
  • Difficulty going to the clinic 3 times per week as required by the protocol.
  • Patients with precoital premature ejaculation.
  • Use of barrier contraceptive methods or local anesthetics.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03204890

Layout table for location information
Boston Medical Group Colombia
Bogotá, Cundinamarca, Colombia, 11022
Sponsors and Collaborators
Boston Medical Group
Layout table for investigator information
Principal Investigator: José P Saffon, Doctor Boston Medical Group
Layout table for additonal information
Responsible Party: Boston Medical Group
ClinicalTrials.gov Identifier: NCT03204890    
Other Study ID Numbers: BMGC-2
First Posted: July 2, 2017    Key Record Dates
Last Update Posted: February 4, 2019
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Premature Birth
Premature Ejaculation
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Sexual Dysfunction, Physiological
Sexual Dysfunctions, Psychological
Mental Disorders